ESMO 2024 | 10-year insights from KEYNOTE-006 and CHECKMATE 067 trials in melanoma
Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands, shares 10-year overall survival (OS) data from the KEYNOTE-006 (NCT01866319) and CHECKMATE 067 (NCT01844505) trials, showing that only 1% of melanoma patients die per year after five years, indicating most are cured. The focus now shifts to managing long-term toxicities like dry mouth, fatigue, and endocrine issues while supporting patient resilience and quality of life. Additionally, improving management of immune-related adverse events, particularly for those on ipilimumab and nivolumab, is critical to further enhancing survival outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
